AbbVie (ABBV) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
AbbVie Inc. (ABBV) insider buying and selling: no purchases, 4 sales
35 Form 4 Table I transactions filed with the SEC by AbbVie Inc. insiders between 2026-02-20 and 2026-08-18 (15-month history): 0 open-market purchases and 4 sales, plus 31 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $8.2M by Donoghoe Nicholas on 2026-08-14.
AbbVie insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, AbbVie insiders filed 4 sales worth $18.9M on the open market, and no purchases.
The biggest seller was Siatis Perry C (EVP, GC AND SECRETARY): $9.5M in 2 sales, out of 3 different sellers.
The largest trade of the period was a sale of $8.2M on Aug 14, 2026, by Donoghoe Nicholas (EVP, CHIEF BUS/STRAT OFFICER). Form 4 on sec.gov (0001762951-26-000006).
Of the 4 sales, 2 (50%, $9.5M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 2 do not.
The last three months show 1 sale, against 0 in the three before. The latest sale from Aug 14, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. AbbVie has more sales than 14 of the other 58, ranks 27 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with ABBV's sales, largest first. The full history is in the tool above, already searched.
See all 35 ABBV trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-08-14 | 2026-08-18 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | $8.2M | S — Open-market sale | SEC |
| 2026-02-25 | 2026-02-27 | Siatis Perry C | EVP, GC AND SECRETARY | $5.1M | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-03-02 | 2026-03-03 | Siatis Perry C | EVP, GC AND SECRETARY | $4.4M | S — Open-market sale (scheduled 10b5-1)3 Form 4 footnotesF1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-03-04 | 2026-03-06 | Purdue David Ryan | SVP, Controller | $1.2M | S — Open-market sale | SEC |
| 2026-02-27 | 2026-03-03 | Michael Robert A. | CHAIRMAN OF THE BOARD AND CEO | $8.5M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-27 | 2026-03-03 | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | $5.5M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-27 | 2026-03-03 | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | $5.0M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-25 | 2026-02-27 | Siatis Perry C | EVP, GC AND SECRETARY | $3.9M | M — Option exercise (scheduled 10b5-1) | SEC |
| 2026-02-27 | 2026-03-03 | Saleki-Gerhardt Azita | EVP, CHIEF OPERATIONS OFFICER | $3.8M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-27 | 2026-03-03 | Siatis Perry C | EVP, GC AND SECRETARY | $3.4M | F — Tax withholding (shares surrendered for taxes) (scheduled 10b5-1) | SEC |
| 2026-02-27 | 2026-03-03 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | $3.0M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-08-14 | 2026-08-18 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | $2.6M | M — Option exercise | SEC |
| 2026-02-27 | 2026-03-03 | Thakkar Roopal | EVP, R&D and CSO | $1.9M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-27 | 2026-03-03 | Purdue David Ryan | SVP, Controller | $625k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-27 | 2026-03-06 | Crum Demetris D | EVP, CHIEF HR OFFICER | $370k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-05-08 | 2026-05-12 | Austin Roxanne S | Director | A — Grant or awardForm 4 footnoteF1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). | SEC | |
| 2026-05-08 | 2026-05-12 | Rapp Edward J | Director | A — Grant or award2 Form 4 footnotesF1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F2 Total holdings include 10,388 shares in trust previously held indirectly by spouse, now held directly. | SEC | |
| 2026-05-08 | 2026-05-12 | Falk Thomas J | Director | A — Grant or awardForm 4 footnoteF1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). | SEC | |
| 2026-05-08 | 2026-05-12 | Waddell Frederick H | Director | A — Grant or awardForm 4 footnoteF1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). | SEC | |
| 2026-05-08 | 2026-05-12 | Freyman Thomas C | Director | A — Grant or awardForm 4 footnoteF1 These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Feb 20, 2026 and Aug 18, 2026 there is not one open-market purchase of AbbVie Inc.: 4 sales worth $18.9M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like AbbVie Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| A | Grant or award | 20 | $0 |
| F | Tax withholding (shares surrendered for taxes) | 9 | $32.1M |
| S | Open-market sale | 4 | $18.9M |
| M | Option exercise | 2 | $6.4M |
| Total | Everything filed in the period | 35 | $57.5M |
20 of the 35 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 20 distinct people or entities have filed AbbVie Inc. transactions: none bought on the open market and 3 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Siatis Perry C | EVP, GC AND SECRETARY | 5 | — | $9.5M (2) | 2026-03-03 |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 4 | — | $8.2M (1) | 2026-08-18 |
| Purdue David Ryan | SVP, Controller | 3 | — | $1.2M (1) | 2026-03-06 |
| Crum Demetris D | EVP, CHIEF HR OFFICER | 2 | — | — | 2026-03-06 |
| Michael Robert A. | CHAIRMAN OF THE BOARD AND CEO | 2 | — | — | 2026-03-03 |
| Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | 2 | — | — | 2026-03-03 |
| Saleki-Gerhardt Azita | EVP, CHIEF OPERATIONS OFFICER | 2 | — | — | 2026-03-03 |
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 2 | — | — | 2026-03-03 |
Shown here are the 8 who moved the most money, out of 20. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Mar 2026: 0 purchases and 2 sales, worth $5.6M. 12 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 0 | $0 |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 1 | $5.1M |
| Mar 2026 | 0 | $0 | 2 | $5.6M |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 0 | $0 |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 1 | $8.2M |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
AbbVie Inc. (ABBV) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
2 of the 4 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. AbbVie has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Aug 18, 2026, and a Form 4 arrives up to two business days after the trade.
6 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.